Aldeyra Therapeutics (NASDAQ: ALDX) reported Q3 EPS of ($0.32), $0.05 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.